Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3

Journal of Investigative Dermatology

Volumn 134, Issue 7, 2014, Pages 1893-1902

  Camisaschi, Chiara ^a   De Filippo, Annamaria ^a   Beretta, Valeria ^a   Vergani, Barbara ^b   Villa, Antonello ^b   Vergani, Elisabetta ^a   Santinami, Mario ^a   Cabras, Antonello Domenico ^a   Arienti, Flavio ^a   Triebel, Frédéric ^c   Rodolfo, Monica ^a   Rivoltini, Licia ^a   Castelli, Chiara ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; TOLL LIKE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL SUBPOPULATION; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPH NODE; LYMPHOCYTE ACTIVATION; MELANOMA CELL; METASTATIC MELANOMA; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; CHEMOKINE CCL2; COS CELLS; DENDRITIC CELLS; HUMANS; INTERLEUKIN-6; MELANOMA; MONOCYTES; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84902547851     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.29     Document Type: Article

References (60)

1. Barrat FJ, Meeker T, Gregorio J et al. (2005) Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202: 1131-9
2. Becker JC, Termeer C, Schmidt RE et al. (1993) Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151: 7224-32
3. Blackburn SD, Shin H, Haining WN et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29-37
4. Brocker EB, Suter L, Sorg C (1984) HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 82: 244-7
5. Camisaschi C, Casati C, Rini F et al. (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184: 6545-51
6. Casati C, Camisaschi C, Rini F et al. (2006) Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 66: 4450-60
7. Casati C, Dalerba P, Rivoltini L et al. (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 63: 4507-15
8. Cella M, Jarrossay D, Facchetti F et al. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5: 919-23
9. Charles J, Di Domizio J, Salameire D et al. (2010) Characterization of circulating dendritic cells in melanoma: Role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 130: 1646-56
10. De Filippo A, Binder RJ, Camisaschi C et al. (2008) Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol 181: 6525-35
11. Decalf J, Fernandes S, Longman R et al. (2007) Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 204: 2423-37
12. Demoulin S, Herfs M, Delvenne P et al. (2013) Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 93: 343-52
13. Drobits B, Holcmann M, Amberg N et al. (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumorkilling effector cells. J Clin Invest 122: 575-85
14. Fabricius D, Neubauer M, Mandel B et al. (2010) Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol 184: 677-84
15. Faget J, Bendriss-Vermare N, Gobert M et al. (2012) ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 72: 6130-41
16. Gagliani N, Magnani CF, Huber S et al. (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19: 739-46
17. Gerlini G, Di Gennaro P, Mariotti G et al. (2010) Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes. J Invest Dermatol 130: 898-901
18. Gerlini G, Urso C, Mariotti G et al. (2007) Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 125: 184-93
19. Grage-Griebenow E, Loseke S, Kauth M et al. (2007) Anti-BDCA-4 (neuropilin-1) antibody can suppress virus-induced IFN-alpha production of plasmacytoid dendritic cells. Immunol Cell Biol 85: 383-90
20. Grosso JF, Kelleher CC, Harris TJ et al. (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117: 3383-92
21. Guerry D 4th, Alexander MA, Elder DE et al. (1987) Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol 139: 305-12
22. Hadeiba H, Lahl K, Edalati A et al. (2012) Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity 36: 438-50
23. Hartmann E, Wollenberg B, Rothenfusser S et al. (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478-87
24. Hemon P, Jean-Louis F, Ramgolam K et al. (2011) MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 186: 5173-83
25. Huang B, Lei Z, Zhao J et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86-92
26. Huard B, Mastrangeli R, Prigent P et al. (1997) Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA 94: 5744-9
27. Jahrsdorfer B, Vollmer A, Blackwell SE et al. (2010) Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115: 1156-65
28. Jensen TO, Schmidt H, Moller HJ et al. (2012) Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118: 2476-2476
29. Kadowaki N, Antonenko S, Lau JY et al. (2000) Natural interferon alpha/betaproducing cells link innate and adaptive immunity. J Exp Med 192: 219-219
30. Karrich JJ, Jachimowski LC, Nagasawa M et al. (2013) IL-21-stimulated human plasmacytoid dendritic cells secrete granzyme B, which impairs their capacity to induce T-cell proliferation. Blood 121: 3103-11
31. Knight DA, Ngiow SF, Li M et al. (2013) Host immunity contributes to the antimelanoma activity of BRAF inhibitors. J Clin Invest 123:3182
32. Kurbanov BM, Fecker LF, Geilen CC et al. (2007) Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 26: 3364-77
33. Labidi-Galy SI, Sisirak V, Meeus P et al. (2011) Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 71: 5423-34
34. Le Mercier I, Poujol D, Sanlaville A et al. (2013) Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 73: 4629-40
35. Maazi H, Lam J, Lombardi V et al. (2013) Role of plasmacytoid dendritic cell subsets in allergic asthma. Allergy 68: 695-701
36. Maccalli C, Li YF, El-Gamil M et al. (2003) Identification of a colorectal tumorassociated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 63: 6735-43
37. Matsui T, Connolly JE, Michnevitz M et al. (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 182: 6815-23
38. Nestle FO, Conrad C, Tun-Kyi A et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202: 135-135
39. Piqueras B, Connolly J, Freitas H et al. (2006) Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107: 2613-8
40. Popovic PJ, DeMarco R, Lotze MT et al. (2006) High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol 177: 8701-7
41. Roca H, Varsos ZS, Sud S et al. (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284: 34342-54
42. Ruiter DJ, Mattijssen V, Broecker EB et al. (1991) MHC antigens in human melanomas. Semin Cancer Biol 2: 35-45
43. Sansom DM, Manzotti CN, Zheng Y (2003) What's the difference between CD80 and CD86? Trends Immunol 24: 314-9
44. Shin A, Toy T, Rothenfusser S et al. (2008) P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells. Blood 111: 3062-9
45. Siegal FP, Kadowaki N, Shodell M et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-7
46. Sisirak V, Faget J, Gobert M et al. (2012) Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 72: 5188-97
47. Sozzani S, Vermi W, Del Prete A et al. (2010) Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol 31: 270-7
48. Swiecki M, Colonna M (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 234: 142-62
49. Tel J, Aarntzen EH, Baba T et al. (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73: 1063-75
50. Treilleux I, Blay JY, Bendriss-Vermare N et al. (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10: 7466-74
51. Triebel F (2003) LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24: 619-22
52. Tsukamoto N, Okada S, Onami Y et al. (2009) Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res 15: 5733-5733
53. van Duinen SG, Ruiter DJ, Broecker EB et al. (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48: 1019-25
54. van Vreeswijk H, Ruiter DJ, Brocker EB et al. (1988) Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 90: 755-60
55. Vermi W, Bonecchi R, Facchetti F et al. (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200: 255-255
56. Vermi W, Fisogni S, Salogni L et al. (2011) Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 131: 426-34
57. Vermi W, Soncini M, Melocchi L et al. (2011) Plasmacytoid dendritic cells and cancer. J Leukoc Biol 90: 681-90
58. Workman CJ, Wang Y, El Kasmi KC et al. (2009) LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 182: 1885-91
59. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809
60. Zheng Y, Manzotti CN, Liu M et al. (2004) CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 172: 2778-84